Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

ORKA

Oruka Therapeutics (ORKA)

Oruka Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ORKA
FechaHoraFuenteTítuloSímboloCompañía
24/01/202515:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORKAOruka Therapeutics Inc
19/12/202406:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORKAOruka Therapeutics Inc
19/12/202406:00GlobeNewswire Inc.Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 AntibodyNASDAQ:ORKAOruka Therapeutics Inc
18/12/202406:00GlobeNewswire Inc.Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)NASDAQ:ORKAOruka Therapeutics Inc
26/11/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORKAOruka Therapeutics Inc
21/11/202417:30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ORKAOruka Therapeutics Inc
19/11/202407:00GlobeNewswire Inc.Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare ConferenceNASDAQ:ORKAOruka Therapeutics Inc
14/11/202418:38Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ORKAOruka Therapeutics Inc
14/11/202416:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ORKAOruka Therapeutics Inc
14/11/202405:37Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ORKAOruka Therapeutics Inc
13/11/202415:25GlobeNewswire Inc.Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ORKAOruka Therapeutics Inc
13/11/202415:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORKAOruka Therapeutics Inc
04/11/202406:00GlobeNewswire Inc.Oruka Therapeutics to Present at Multiple November Investor ConferencesNASDAQ:ORKAOruka Therapeutics Inc
18/10/202415:11Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ORKAOruka Therapeutics Inc
25/09/202406:08GlobeNewswire Inc.Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology CongressNASDAQ:ORKAOruka Therapeutics Inc
12/09/202406:05GlobeNewswire Inc.Oruka Therapeutics Announces $200 Million Private PlacementNASDAQ:ORKAOruka Therapeutics Inc
12/09/202406:00GlobeNewswire Inc.Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19NASDAQ:ORKAOruka Therapeutics Inc
06/09/202416:08Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:ORKAOruka Therapeutics Inc
06/09/202416:07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ORKAOruka Therapeutics Inc
03/09/202406:00GlobeNewswire Inc.Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 MillionNASDAQ:ORKAOruka Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ORKA